Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.36 |
| ▸ | DUSP10 | Q9Y6W6 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13629289 | 0.75 | CYP1A2 (0.54) | CYP1A2SMN1; SMN2ALDH1A1ALOX15MAPK10 | |
| SCHEMBL13629292 | 0.72 | CYP1A2 (0.43) | CYP1A2SMN1; SMN2ALDH1A1ALOX15MAPK10 | |
| SCHEMBL13629274 | 0.70 | CYP1A2 (0.54) | CYP1A2SMN1; SMN2ALDH1A1ALOX15MAPK10 | |
| SCHEMBL11985681 | 0.70 | CYP1A2 (0.40) | CYP1A2SMN1; SMN2ALDH1A1ALOX15MAPK10 | |
| SCHEMBL299004 | 0.69 | PARP1 (0.53) | CYP1A2PDPK1PARP1PARP10PARP11 | |
| SCHEMBL299769 | 0.67 | TDP2 (0.52) | CYP1A2SMN1; SMN2ALDH1A1ALOX15MAPK10 | |
| SCHEMBL22579802 | 0.67 | TDP1 (0.42) | SMN1; SMN2ALOX15MAPK14DUSP10LMNA | |
| SCHEMBL6385750 | 0.66 | CES1 (0.59) | ALDH1A1MAPK14MAPK1GAACES1 | |
| SCHEMBL2715285 | 0.66 | PARP1 (0.46) | GAATDP2PDPK1PARP1PARP10 | |
| SCHEMBL29807425 | 0.66 | TDP2 (0.45) | CYP1A2ALDH1A1MAPK14GAATDP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7790739-B2 | receptor tyrosine kinase MET inhibitors; anticancer agents; 8-phenyl-10H-furo[2',3':4,5]cyclohepta[1,2-b]pyridin-10-one | Merck & Co., Inc. and Merck Sharp & Dohme Corp. (US) | 2010-09-07 | — | — | US | disclosed |
| US-7790739-B2 | receptor tyrosine kinase MET inhibitors; anticancer agents; 8-phenyl-10H-furo[2',3':4,5]cyclohepta[1,2-b]pyridin-10-one | Merck & Co., Inc. and Merck Sharp & Dohme Corp. (US) | 2010-09-07 | — | — | US | disclosed |
| US-20090247565-A1 | Tyrosine Kinase Inhibitors | MERCK SHARP & DOHME CORP. | 2009-10-01 | — | — | US | disclosed |
| US-20090247565-A1 | Tyrosine Kinase Inhibitors | MERCK SHARP & DOHME CORP. | 2009-10-01 | — | — | US | disclosed |
| WO-2007050380-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2007-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247565-A1 | Tyrosine Kinase Inhibitors | ABL1, ERBB2, MET | CYP1A2 4074/4885SMN1; SMN2 3373/4885ALDH1A1 1458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.